Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

Stem-cell therapy for Parkinson's shows 'strong promise' in relieving symptoms

Researchers at Memorial Sloan Kettering Cancer Center have developed a new therapy that uses stem cells to treat advanced Parkinson’s symptoms. The study author and other doctors discuss the outcomes.

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

Parkinson’s disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns1–5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments6. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50–69) received bilateral transplantation of dopaminergic progenitors d…

Dr. Vincent Valinducq tells us about the beginning of a revolution in the management of patients with Parkinson's disease. Two teams of researchers have succeeded in grafting neurons that secrete dopamine into the brains of patients. (Health and well-being).

Kyoto University, CiRA trial of iPS therapy shows promise in Parkinson's

A Phase I/II trial by Japan’s Kyoto University Hospital and CiRA team has demonstrated outcomes with allogeneic iPS cell-based cells.The post Kyoto University, CiRA trial of iPS therapy shows promise in Parkinson’s appeared first on Clinical Trials Arena.